144
Participants
Start Date
September 26, 2017
Primary Completion Date
November 19, 2018
Study Completion Date
February 1, 2019
Leuprolide Mesylate
Subcutaneous injection of 25mg Leuprolide Mesylate
National Cancer Center, Gyeonggi-do
Seoul National University Bundang Hosptal, Gyeonggi-do
Hallym University Sacred Heart Hospital, Gyeonggi-do
Urology of Virginia, PLLC, Virginia Beach
Carolina Clinical Trials, LLC, Concord
Urology Centers of Alabama, Homewood
Keimyung University Dongsan Medical Center, Daegu
Pusan National University Hospital, Busan
Hospital of Lithuanian University of Health Sciences Kauno klinikos, Kaunas
Urology San Antonio, P.A, San Antonio
The Urology Center of Colorado, Denver
Arizona Institute of Urology, Tucson
Klaipėda University Hospital, Klaipėda
Fakultní nemocnice Hradec Králové, Urologická klinika, Hradec Králové
Uromedical Center Olomouc, Olomouc
Thomayerova nemocnice, Urologické oddělení, Prague
National Cancer Institute, Vilnius
Vilnius University Hospital, Santaros klinikos, Vilnius
UROCENTRUM MILAB, s.r.o., Prešov
Fakultná nemocnica s poliklinikou Žilina Urológia, Žilina
Korea University Anam Hospital, Seoul
Lead Sponsor
Foresee Pharmaceuticals Co., Ltd.
INDUSTRY